Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-29T11:17:36.502Z Has data issue: false hasContentIssue false

P-907 - Escitalopram Monotherapy in Managing Depressive and Pain Symptoms in Patients With Depression and Fibromyalgia

Published online by Cambridge University Press:  15 April 2020

N. Krapivensky
Affiliation:
Clinical Psychiatry, International Institute of Psychopharmacology, North Caulfield, VIC, Australia
D. Lewis
Affiliation:
Clinical Psychiatry, International Institute of Psychopharmacology, North Caulfield, VIC, Australia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Fibromyalgia is characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance, headaches, and cognitive and affective disturbance. The aetiological pathway is not clearly understood nor is there a clearly defined pathophysiological profile for the disorder that distinguishes it as a diagnosis.

Objectives

To investigate the efficacy of 20 mg escitalopram monotherapy in management of depressive symptoms, pain, fatigue and sleep.

Aims

To demonstrate efficacy of escitalopram in improving depressive and pain symptoms as measured by primary and secondary outcome measures.

Methods

60 subjects were randomized to treatment or control group and evaluated at 4,8 and 12 weeks using MADRAS, McGill pain questionnaire, fibromyalgia impact score and sleep questionnaires.

Results

Mean MADRAS score was significantly lower in the treatment group (14.96 ± 1.02 vs 18.12 ± 1.05; p = 0.03) as compared to the control group. When the change from baseline on MADRAS score was compared between the groups, the reduction was even more apparent in the treatment group (−12.49 ± 1.48 vs − 4.77 ± 1.54; p = 0.001).Mean FIBROMYALGIA score was significantly lower in the treatment group as compared to the control group (54.20 ± 2.09 vs 64.93 ± 2.14; p < 0.001). The reduction was much higher in the treatment group than the control group (−21.31 ± 2.94 vs − 2.79 ± 3.03; p < 0.001).

Conclusion

Positive statistically significant results for treatment group on all primary outcome measures of MADRAS and fibromyalgia impact score questionnaire.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.